Details of the Drug

General Information of Drug (ID: DMLMXE0)

Drug Name
Amprenavir
Synonyms
AMV; Agenerase; Amprenavir[usan]; Prozei; Vertex; Amprenavir [USAN]; VX 478; VX478; Vertex VX478; Agenerase (TM); Agenerase (TN); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; VX-478; Amprenavir (JAN/USAN/INN); Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
Therapeutic Class
Anti-HIV Agents
Affected Organisms
Human Immunodeficiency Virus
ATC Code
J05AE05: Amprenavir
J05AE: Protease inhibitors
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 505.6
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 12
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.1 - 10.6 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 67.80681 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.04 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Insulin resistance Not Available ADIPOQ OTNX23LE [6]
Insulin resistance Not Available LPL OTTW0267 [6]
Chemical Identifiers
Formula
C25H35N3O6S
IUPAC Name
[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
Canonical SMILES
CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
InChI
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
InChIKey
YMARZQAQMVYCKC-OEMFJLHTSA-N
Cross-matching ID
PubChem CID
65016
ChEBI ID
CHEBI:40050
CAS Number
161814-49-9
UNII
5S0W860XNR
DrugBank ID
DB00701
TTD ID
D0A0OO
VARIDT ID
DR00584
INTEDE ID
DR0107
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Protease (HIV PR) TT5FNQT POL_HV1B1 Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Drug Response [6]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [12]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [13]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [14]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Gene/Protein Processing [14]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [15]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Drug Response [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amprenavir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
MK-1439 DM215WE Minor Decreased metabolism of Amprenavir caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Delavirdine DM3NF5G Major Decreased metabolism of Amprenavir caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Amprenavir caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [18]
Dolutegravir DMCZGRE Minor Decreased metabolism of Amprenavir caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Etravirine DMGV8QU Moderate Increased metabolism of Amprenavir caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Didanosine DMI2QPE Moderate Decreased absorption of Amprenavir due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [17]
Lopinavir DMITQS0 Major Increased metabolism of Amprenavir caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Maraviroc DMTL94F Major Decreased metabolism of Amprenavir caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Amprenavir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Amprenavir due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [17]
Clindamycin DM15HL8 Moderate Decreased metabolism of Amprenavir caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [23]
Tretinoin DM49DUI Moderate Decreased metabolism of Amprenavir caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [24]
Repaglinide DM5SXUV Moderate Antagonize the effect of Amprenavir when combined with Repaglinide. Acute diabete complication [5A2Y] [25]
Ivosidenib DM8S6T7 Major Increased metabolism of Amprenavir caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [21]
Midostaurin DMI6E0R Moderate Decreased metabolism of Amprenavir caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Arn-509 DMT81LZ Moderate Increased metabolism of Amprenavir caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [27]
Gilteritinib DMTI0ZO Major Decreased metabolism of Amprenavir caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [28]
Oliceridine DM6MDCF Major Decreased metabolism of Amprenavir caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [29]
Donepezil DMIYG7Z Minor Decreased metabolism of Amprenavir caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [30]
Metronidazole DMTIVEN Major Decreased metabolism of Amprenavir caused by Metronidazole mediated inhibition of non-CYP450 enzyme. Amoebiasis [1A36] [17]
Ivabradine DM0L594 Major Decreased metabolism of Amprenavir caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [18]
Bepridil DM0RKS4 Major Decreased metabolism of Amprenavir caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [21]
Dronedarone DMA8FS5 Major Decreased metabolism of Amprenavir caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [18]
Nifedipine DMSVOZT Moderate Decreased metabolism of Amprenavir caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Moderate Decreased metabolism of Amprenavir caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [31]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Amprenavir caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [32]
Halazepam DMPFWO6 Moderate Decreased metabolism of Amprenavir caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [17]
Cilostazol DMZMSCT Major Decreased metabolism of Amprenavir caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [33]
Posaconazole DMUL5EW Moderate Decreased metabolism of Amprenavir caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [33]
Budesonide DMJIBAW Moderate Decreased metabolism of Amprenavir caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [34]
Tindamax DM3OWT4 Major Decreased metabolism of Amprenavir caused by Tindamax mediated inhibition of non-CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Dalfopristin DM4LTKV Minor Decreased metabolism of Amprenavir caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Clarithromycin DM4M1SG Minor Decreased metabolism of Amprenavir caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Troleandomycin DMUZNIG Minor Decreased metabolism of Amprenavir caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Cariprazine DMJYDVK Major Decreased metabolism of Amprenavir caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [37]
Erdafitinib DMI782S Major Decreased metabolism of Amprenavir caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [38]
Pexidartinib DMS2J0Z Major Decreased metabolism of Amprenavir caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [39]
Loperamide DMOJZQ9 Major Decreased metabolism of Amprenavir caused by Loperamide mediated inhibition of CYP450 enzyme. Bowel habit change [ME05] [40]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Amprenavir caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Lapatinib DM3BH1Y Major Decreased metabolism of Amprenavir caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
HKI-272 DM6QOVN Major Decreased metabolism of Amprenavir caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
LY2835219 DM93VBZ Moderate Decreased metabolism of Amprenavir caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Palbociclib DMD7L94 Major Decreased metabolism of Amprenavir caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Amprenavir caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Bosutinib DMTI8YE Major Decreased metabolism of Amprenavir caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Amprenavir caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Atorvastatin DMF28YC Major Decreased metabolism of Amprenavir caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [45]
Macitentan DMP79A1 Major Decreased metabolism of Amprenavir caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [46]
PF-04449913 DMSB068 Moderate Decreased metabolism of Amprenavir caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [47]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Amprenavir caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [48]
Salmeterol DMIEU69 Major Decreased metabolism of Amprenavir caused by Salmeterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [18]
Revefenacin DMMP5SI Moderate Decreased clearance of Amprenavir due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [49]
Indacaterol DMQJHR7 Minor Decreased metabolism of Amprenavir caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [50]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Amprenavir caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [32]
Levomilnacipran DMV26S8 Major Decreased metabolism of Amprenavir caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [51]
Regorafenib DMHSY1I Moderate Decreased metabolism of Amprenavir caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [18]
Irinotecan DMP6SC2 Major Decreased metabolism of Amprenavir caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [21]
Drospirenone DM1A9W3 Major Decreased metabolism of Amprenavir caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [18]
Levobupivacaine DM783CH Moderate Decreased metabolism of Amprenavir caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [33]
Cocaine DMSOX7I Moderate Decreased metabolism of Amprenavir caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [17]
Alfentanil DMVO0UB Major Decreased metabolism of Amprenavir caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [52]
Mifepristone DMGZQEF Major Decreased metabolism of Amprenavir caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [53]
Osilodrostat DMIJC9X Major Decreased metabolism of Amprenavir caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [54]
Ivacaftor DMZC1HS Major Decreased metabolism of Amprenavir caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [18]
MK-8228 DMOB58Q Moderate Decreased metabolism of Amprenavir caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [55]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Amprenavir caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [18]
Vilazodone DM4LECQ Major Decreased metabolism of Amprenavir caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
Nefazodone DM4ZS8M Minor Decreased metabolism of Amprenavir caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [36]
Escitalopram DMFK9HG Minor Decreased metabolism of Amprenavir caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [57]
OPC-34712 DMHG57U Major Decreased metabolism of Amprenavir caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Amprenavir caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [59]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Amprenavir due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [17]
Ospemifene DMC4GEI Moderate Decreased metabolism of Amprenavir caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [60]
Diazepam DM08E9O Moderate Decreased metabolism of Amprenavir caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Amprenavir caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Primidone DM0WX6I Moderate Increased metabolism of Amprenavir caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Felbamate DM1V5ZS Moderate Increased metabolism of Amprenavir caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Amprenavir caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Cenobamate DM8KLU9 Moderate Increased metabolism of Amprenavir caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Amprenavir caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Stiripentol DMMSDOY Moderate Decreased metabolism of Amprenavir caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Amprenavir caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Clonazepam DMTO13J Moderate Decreased metabolism of Amprenavir caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Lacosamide DMVM6QR Moderate Decreased metabolism of Amprenavir caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Phenobarbital DMXZOCG Moderate Increased metabolism of Amprenavir caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Cannabidiol DM0659E Minor Decreased metabolism of Amprenavir caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [33]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Amprenavir caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [63]
Tazemetostat DMWP1BH Major Decreased metabolism of Amprenavir caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [64]
Solifenacin DMG592Q Major Decreased metabolism of Amprenavir caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [18]
Mirabegron DMS1GYT Minor Decreased metabolism of Amprenavir caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [65]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Amprenavir caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [66]
Itraconazole DMCR1MV Moderate Decreased metabolism of Amprenavir caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Miconazole DMPMYE8 Minor Decreased metabolism of Amprenavir caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [17]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Amprenavir caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Ripretinib DM958QB Major Decreased metabolism of Amprenavir caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Sunitinib DMCBJSR Moderate Decreased metabolism of Amprenavir caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
Avapritinib DMK2GZX Major Decreased metabolism of Amprenavir caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [33]
Colchicine DM2POTE Major Decreased metabolism of Amprenavir caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [67]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Amprenavir caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [32]
Simeprevir DMLUA9D Major Decreased metabolism of Amprenavir caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Amprenavir caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
GS-9857 DMYU6P5 Moderate Decreased clearance of Amprenavir due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [68]
Rifampin DMA8J1G Major Increased metabolism of Amprenavir caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [69]
Rifapentine DMCHV4I Major Increased metabolism of Amprenavir caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [27]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Amprenavir caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [33]
Rosuvastatin DMMIQ7G Major Decreased clearance of Amprenavir due to the transporter inhibition by Rosuvastatin. Hyper-lipoproteinaemia [5C80] [18]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Amprenavir caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [70]
Paricalcitol DMYBV3G Moderate Decreased metabolism of Amprenavir caused by Paricalcitol mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [33]
Aliskiren DM1BV7W Moderate Decreased metabolism of Amprenavir caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [21]
Levamlodipine DM92S6N Moderate Decreased metabolism of Amprenavir caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [21]
Conivaptan DM1V329 Major Decreased metabolism of Amprenavir caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [18]
Tolvaptan DMIWFRL Major Decreased metabolism of Amprenavir caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [18]
Retapamulin DM9JXB7 Minor Decreased metabolism of Amprenavir caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [71]
Lesinurad DMUR64T Moderate Increased metabolism of Amprenavir caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [32]
TP-434 DM5A31S Minor Decreased metabolism of Amprenavir caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [72]
Suvorexant DM0E6S3 Major Decreased metabolism of Amprenavir caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [73]
Amobarbital DM0GQ8N Moderate Increased metabolism of Amprenavir caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [32]
Ramelteon DM7IW9J Moderate Decreased metabolism of Amprenavir caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Triazolam DMETYK5 Major Decreased metabolism of Amprenavir caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Amprenavir caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
ITI-007 DMUQ1DO Major Decreased metabolism of Amprenavir caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [76]
Quazepam DMY4D87 Moderate Decreased metabolism of Amprenavir caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Estazolam DMZGXUM Moderate Decreased metabolism of Amprenavir caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [17]
Alosetron DML2A03 Moderate Decreased metabolism of Amprenavir caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [77]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Amprenavir caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [78]
Naloxegol DML0B41 Major Decreased metabolism of Amprenavir caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [18]
Pemigatinib DM819JF Major Decreased metabolism of Amprenavir caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [79]
Crizotinib DM4F29C Major Decreased metabolism of Amprenavir caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
Brigatinib DM7W94S Major Decreased metabolism of Amprenavir caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [80]
Ceritinib DMB920Z Major Decreased metabolism of Amprenavir caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Amprenavir caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [81]
PF-06463922 DMKM7EW Moderate Increased metabolism of Amprenavir caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [27]
Osimertinib DMRJLAT Major Decreased metabolism of Amprenavir caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [82]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Amprenavir due to the transporter induction by BIBW 2992. Lung cancer [2C25] [83]
Pralsetinib DMWU0I2 Major Decreased metabolism of Amprenavir caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
Capmatinib DMYCXKL Major Decreased metabolism of Amprenavir caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
Selpercatinib DMZR15V Major Decreased metabolism of Amprenavir caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [86]
Artemether DM48QOT Major Decreased metabolism of Amprenavir caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [18]
Halofantrine DMOMK1V Major Decreased metabolism of Amprenavir caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [87]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Amprenavir caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [18]
Idelalisib DM602WT Moderate Decreased metabolism of Amprenavir caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [88]
GDC-0199 DMH0QKA Major Decreased metabolism of Amprenavir caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [18]
IPI-145 DMWA24P Moderate Decreased metabolism of Amprenavir caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [89]
Acalabrutinib DM7GCVW Major Decreased metabolism of Amprenavir caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [90]
Ibrutinib DMHZCPO Major Decreased metabolism of Amprenavir caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [91]
Ponatinib DMYGJQO Major Decreased metabolism of Amprenavir caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [18]
Arry-162 DM1P6FR Moderate Accelerated clearance of Amprenavir due to the transporter induction by Arry-162. Melanoma [2C30] [18]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Amprenavir caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [92]
Selumetinib DMC7W6R Major Decreased metabolism of Amprenavir caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [93]
LGX818 DMNQXV8 Major Decreased metabolism of Amprenavir caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [94]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Amprenavir caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [18]
Danazol DML8KTN Minor Decreased metabolism of Amprenavir caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [17]
Ubrogepant DM749I3 Moderate Decreased metabolism of Amprenavir caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [95]
Almogran DM7I64Z Moderate Decreased metabolism of Amprenavir caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [96]
Rimegepant DMHOAUG Moderate Decreased metabolism of Amprenavir caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [97]
Exjade DMHPRWG Moderate Decreased metabolism of Amprenavir caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [98]
Flibanserin DM70DTN Major Decreased metabolism of Amprenavir caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [99]
Panobinostat DM58WKG Moderate Decreased metabolism of Amprenavir caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [100]
Siponimod DM2R86O Major Decreased metabolism of Amprenavir caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [18]
Deflazacort DMV0RNS Major Decreased metabolism of Amprenavir caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [33]
Romidepsin DMT5GNL Moderate Decreased metabolism of Amprenavir caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [101]
Fedratinib DM4ZBK6 Major Decreased metabolism of Amprenavir caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [33]
Nilotinib DM7HXWT Major Decreased metabolism of Amprenavir caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Ruxolitinib DM7Q98D Major Decreased metabolism of Amprenavir caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Dasatinib DMJV2EK Major Decreased metabolism of Amprenavir caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Vorapaxar DMA16BR Major Decreased metabolism of Amprenavir caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [18]
Modafinil DMYILBE Moderate Increased metabolism of Amprenavir caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [62]
Netupitant DMEKAYI Minor Decreased metabolism of Amprenavir caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [103]
Entrectinib DMMPTLH Major Decreased metabolism of Amprenavir caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [33]
Sibutramine DMFJTDI Minor Decreased metabolism of Amprenavir caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [104]
Orlistat DMRJSP8 Moderate Altered absorption of Amprenavir caused by Orlistat. Obesity [5B80-5B81] [105]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Amprenavir caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [106]
S-297995 DM26IH8 Moderate Decreased metabolism of Amprenavir caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [33]
Olaparib DM8QB1D Major Decreased metabolism of Amprenavir caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [18]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Amprenavir caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [107]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Amprenavir caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [108]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Amprenavir caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [109]
Istradefylline DM20VSK Major Decreased metabolism of Amprenavir caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [110]
Pimavanserin DMR7IVC Major Decreased metabolism of Amprenavir caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [111]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Amprenavir caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [17]
Abametapir DM2RX0I Moderate Decreased metabolism of Amprenavir caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [112]
Lefamulin DME6G97 Major Decreased clearance of Amprenavir due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [113]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Amprenavir caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [114]
Ergonovine DM0VEC1 Major Decreased metabolism of Amprenavir caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [115]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Amprenavir caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [116]
ABIRATERONE DM8V75C Minor Decreased metabolism of Amprenavir caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [117]
Enzalutamide DMGL19D Moderate Increased metabolism of Amprenavir caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [27]
Darolutamide DMV7YFT Minor Decreased metabolism of Amprenavir caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [118]
Tamsulosin DM5QF9V Major Decreased metabolism of Amprenavir caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [18]
Silodosin DMJSBT6 Major Decreased metabolism of Amprenavir caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [18]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Amprenavir caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [119]
Ambrisentan DMD1QXW Minor Decreased metabolism of Amprenavir caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [120]
Riociguat DMXBLMP Moderate Decreased metabolism of Amprenavir caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [18]
Everolimus DM8X2EH Major Decreased metabolism of Amprenavir caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Axitinib DMGVH6N Major Decreased metabolism of Amprenavir caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Temsirolimus DMS104F Major Increased metabolism of Amprenavir caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Amprenavir caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [114]
Upadacitinib DM32B5U Major Decreased metabolism of Amprenavir caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [121]
Tofacitinib DMBS370 Major Decreased metabolism of Amprenavir caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [18]
Dexamethasone DMMWZET Moderate Decreased metabolism of Amprenavir caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [18]
Quetiapine DM1N62C Major Decreased metabolism of Amprenavir caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [122]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Amprenavir caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [123]
Iloperidone DM6AUFY Major Decreased metabolism of Amprenavir caused by Iloperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [124]
Pimozide DMW83TP Major Decreased metabolism of Amprenavir caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [18]
Fentanyl DM8WAHT Major Decreased metabolism of Amprenavir caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [18]
Sufentanil DMU7YEL Moderate Decreased metabolism of Amprenavir caused by Sufentanil mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [125]
Avanafil DM75CXN Major Decreased metabolism of Amprenavir caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [126]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Amprenavir caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [127]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Amprenavir caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [128]
Voxelotor DMCS6M5 Major Decreased metabolism of Amprenavir caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [129]
LDE225 DMM9F25 Major Decreased metabolism of Amprenavir caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [130]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Amprenavir caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [33]
Larotrectinib DM26CQR Major Decreased metabolism of Amprenavir caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Methylprednisolone DM4BDON Major Decreased metabolism of Amprenavir caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [114]
Docetaxel DMDI269 Major Decreased metabolism of Amprenavir caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [131]
Trabectedin DMG3Y89 Major Decreased metabolism of Amprenavir caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Armodafinil DMGB035 Moderate Decreased metabolism of Amprenavir caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [62]
LEE011 DMMX75K Major Decreased metabolism of Amprenavir caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [33]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Amprenavir caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [132]
Taxol DMUOT9V Major Decreased metabolism of Amprenavir caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [133]
Pitolisant DM8RFNJ Moderate Increased metabolism of Amprenavir caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [33]
Disulfiram DMCL2OK Major Decreased metabolism of Amprenavir caused by Disulfiram mediated inhibition of non-CYP450 enzyme. Substance abuse [6C40] [17]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Amprenavir caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [18]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Amprenavir caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [134]
As-1670542 DMV05SW Moderate Decreased metabolism of Amprenavir caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [33]
Apixaban DM89JLN Moderate Decreased metabolism of Amprenavir caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [33]
Brilinta DMBR01X Moderate Decreased metabolism of Amprenavir caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [33]
Cabozantinib DMIYDT4 Major Decreased metabolism of Amprenavir caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [18]
Sirolimus DMGW1ID Major Decreased metabolism of Amprenavir caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [18]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Amprenavir caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [135]
Saxagliptin DMGXENV Moderate Decreased metabolism of Amprenavir caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [33]
Elagolix DMB2C0E Moderate Increased metabolism of Amprenavir caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [32]
Fluticasone DMGCSVF Major Decreased metabolism of Amprenavir caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [136]
Betrixaban DM2C4RF Moderate Accelerated clearance of Amprenavir due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [137]
Propafenone DMPIBJK Moderate Decreased metabolism of Amprenavir caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [138]
Amiodarone DMUTEX3 Major Decreased metabolism of Amprenavir caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [21]
⏷ Show the Full List of 227 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 204060.
2 Macrolide treatment for COVID-19: Will this be the way forward BioScience Trends Advance Publication. DOI: 10.5582/bst.2020.03058
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
10 Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
11 Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
12 Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. PLoS One. 2013 Aug 16;8(8):e69394. doi: 10.1371/journal.pone.0069394. eCollection 2013.
13 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
14 Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
15 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
16 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
17 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
18 Cerner Multum, Inc. "Australian Product Information.".
19 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
20 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
21 Canadian Pharmacists Association.
22 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
24 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
25 Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4. [PMID: 9291911]
26 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
27 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
28 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
29 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
30 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
31 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
32 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
35 Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM "Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice." Antimicrob Agents Chemother 46 (2002): 1589-1590. [PMID: 11959608]
36 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
37 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
38 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
39 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
40 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
41 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
42 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
43 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
44 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
45 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
46 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
49 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
50 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
52 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
53 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
54 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
55 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
56 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
57 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
58 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
59 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
60 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
61 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
62 Barry M, Gibbons S, Back D, Mulcahy F "Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations." Clin Pharmacokinet 32 (1997): 194-209. [PMID: 9084959]
63 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
64 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
65 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
66 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
67 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
68 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
69 McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB "Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis." Am J Respir Crit Care Med 154 (1996): 1462-7. [PMID: 8912765]
70 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
71 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
72 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
73 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
74 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
75 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
76 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
77 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
78 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
79 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
80 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
81 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
82 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
83 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
84 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
85 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
87 Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23. [PMID: 12426515]
88 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
89 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
90 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
92 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
93 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
94 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
95 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
96 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
97 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
98 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
100 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
101 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
102 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
103 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
104 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
105 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
106 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
107 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
108 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
109 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
110 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
111 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
112 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
113 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
114 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
115 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
116 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
117 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
118 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
119 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
120 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
121 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
122 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
123 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
124 Product Information. Fanapt (iloperidone). Vanda Pharmaceuticals Inc, Rockville, MD.
125 Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH "Sufentanil disposition. Is it affected by erythromycin administration?" Anesthesiology 78 (1993): 260-5. [PMID: 8439020]
126 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
127 Loulergue P, Gaillard R, Mir O "Interaction involving tadalafil and CYP3A4 inhibition by ritonavir." Scand J Infect Dis 43 (2011): 239-40. [PMID: 20942777]
128 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
129 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
130 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
131 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
132 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
133 Bundow D, Aboulafia DM "Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma." Am J Clin Oncol 27 (2004): 81-4. [PMID: 14758138]
134 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
135 Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5. [PMID: 19709321]
136 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
137 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]
138 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.